Douglas SheridanGlobal Program Leader at RallyBio
Doug has more than 20 years of R&D experience and is a co-inventor of six clinical drug candidates, including an orphan drug approved by the FDA in 2018. Doug recently joined Rallybio, a privately held, development-stage biotech focused on bringing life-transforming medicines to patients with devastating and rare disorders. Prior to Rallybio Doug served as Executive Director, Global Program Team Leader at Alexion Pharmaceuticals, leading the cross-functional development teams responsible for the strategy and execution to launch two global development programs. Doug earned his PhD in Neuroscience from Yale and B.S. in Biochemistry and Molecular Biology from Penn State.